Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Sun Yat-sen University
GlaxoSmithKline
Bristol-Myers Squibb
UNICANCER
Case Comprehensive Cancer Center
Incyte Corporation
Bristol-Myers Squibb
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Sanofi
Merck KGaA, Darmstadt, Germany
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
SWOG Cancer Research Network
European Organisation for Research and Treatment of Cancer - EORTC